Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHTCF.L Regulatory News (HTCF)

  • There is currently no data for HTCF

Monthly Performance Update

21 Aug 2015 07:00

RNS Number : 6803W
BlueCrest AllBlue Fund Ltd
21 August 2015
 



FOR IMMEDIATE RELEASE

 

21 August 2015

 

BLUECREST ALLBLUE FUND LIMITED

FACTSHEET - JULY 2015

 

"Strong gains despite mixed market conditions"

 

BlueCrest AllBlue Fund Limited (BCAB) produced strong gains in July, despite mixed market conditions. BCAB returned 1.8% for the month which brings the year to date return to 2.7% (Sterling Class NAV). The rolling 12 month return was 4.7% and risk measures remained stable.

 

Markets continued to see volatility. Political resolutions in Greece and Iran were overshadowed by a further slump in the Chinese equity market. Economic data was also mixed with generally better data in developed economies offset by worries over Chinese growth and the knock-on effects on commodity prices and other developing economies.

 

"The strongest gains came from systematic funds"

 

All 7 underlying funds rose in July but the strongest gains came from the systematic funds. BlueTrend 2x rose by over 12% (AllBlue now has 5.5% exposure to the 2x leveraged version of BlueTrend) and BlueCrest Quantitative Equity rose by 2.6%.

 

BlueTrend's gains came as more pronounced trends reasserted themselves in markets in July. Particularly strong returns were generated by metals, energy and foreign exchange exposures. Risk levels deployed rose slightly and the model shifted to a net long position in equities during the month and a net short to crops. In other markets, the fund ended the month net long the dollar, fixed income and rates with short positions in metals and energy.

 

BlueCrest Capital International also enjoyed good returns, gaining 1.2% in July. Conditions in developed fixed income markets are increasingly more fruitful and the fund saw particular gains from European trading and cross market strategies. In Europe, the long bias to the short end of the Eurozone was profitable as were the long exposures to Swedish and Swiss rates. All benefited from a "lower for longer" orientation. The allocation committee increased the exposure to BlueCrest Capital International by a further 2% for August to 19%, with a consequent reduction in BlueCrest Quantitative Equity.

 

Despite a treacherous environment in the emerging markets, BlueCrest Emerging Markets Fund recorded a small gain of 0.3% for the month. Conditions, particularly liquidity conditions, were challenging and China dominated sentiment across Asia and into other emerging markets as commodity markets slumped. The fund gained from the China related volatility and also from pricing recovery in CEMEA as the Greek package was finalised.

 

"James Dean appointed to the AllBlue Allocation Committee"

 

James Dean has been appointed to the AllBlue Allocation Committee in place of Matt Weir. Matt is leaving BlueCrest and James is assuming his role as Chief Risk Officer, having been with BlueCrest for 10 years, the last 5 of which have been in the risk department. No changes to controls or processes are occurring.

 

BCAB undertook more repurchases of shares in the market during July as the discount edged out beyond 5%.

Disclaimer:

This document is directed only at: (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005; or (ii) high net worth bodies corporate, unincorporated associations and partnerships and trustees of high value trusts as described in Article 49(2) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and persons who receive this document who do not fall within (i) or (ii) above should not rely on or act upon this document.

 

This document is issued by BlueCrest AllBlue Fund Limited (the "Company") to and for the information of its existing shareholders and does not in any jurisdiction constitute investment advice or an invitation to invest in the shares or any other securities of the Company or any other entity (body corporate or otherwise).

 

The Company has used reasonable care to ensure that the information included in this document is accurate at the date of its issue, but does not undertake to update or revise the information, including any information relating to AllBlue Limited and its underlying funds (the "Funds") provided by BlueCrest Capital Management (UK) LLP or any member of the BlueCrest group of companies (as applicable) ("BlueCrest"), or guarantee the accuracy of such information. To the extent permitted by law neither the Company, the Funds, BlueCrest nor their directors or officers shall be liable for any loss or damage that anyone may suffer in reliance on such information.

 

The information in this document may be changed by the Company at any time. Past performance cannot be relied on as a guide to future performance. The Company's investment strategy is speculative and entails substantial risks. The value of an investment may go down as well as up and some or all of the total amount invested may be lost. This document may not, in whole or in part, directly or indirectly, be taken, transmitted or distributed into the United States of America, its territories or possessions or made available to any national, resident or citizen of the United States of America or any other jurisdiction where applicable laws prohibit its release, distribution or publication. Any failure to comply with these restrictions may be a violation of the law in relevant jurisdictions.

 

JTC (Guernsey) Limited

Secretary

 

Tel: Guernsey 01481 702400

 

END OF ANNOUNCEMENT

E&OE - in transmission

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STRQBLFLEVFFBBE
Date   Source Headline
25th Feb 20161:15 pmRNSNet Asset Value(s)
25th Feb 201610:30 amRNSNet Asset Value(s)
24th Feb 20166:33 pmRNSResults of EGM and Cash Exit
18th Feb 20162:30 pmRNSUpdate re Return of Capital
18th Feb 201612:30 pmRNSNet Asset Value(s)
18th Feb 20169:45 amRNSHolding(s) in Company
12th Feb 20166:30 pmRNSCorrection to Form of Proxy
10th Feb 20165:30 pmRNSNet Asset Value(s)
9th Feb 20162:15 pmRNSNet Asset Value(s)
8th Feb 20164:10 pmRNSPublication of Circular
4th Feb 20164:15 pmRNSNet Asset Value(s)
4th Feb 201610:00 amRNSDirectorate Change
2nd Feb 20162:00 pmRNSUpdate on Continuation Proposals
29th Jan 20166:00 pmRNSTotal Voting Rights
27th Jan 201612:01 pmRNSHolding(s) in Company
27th Jan 201611:50 amRNSNet Asset Value(s)
25th Jan 20162:30 pmRNSUpdate on Continuation Proposals
21st Jan 20165:20 pmRNSNet Asset Value(s)
14th Jan 201611:00 amRNSNet Asset Value(s)
14th Jan 20167:00 amRNSUpdate on Continuation Proposals
12th Jan 201612:00 pmRNSTotal Voting Rights - Corrective Announcement
6th Jan 20164:45 pmRNSNet Asset Value(s)
4th Jan 20167:00 amRNSTotal Voting Rights
31st Dec 20151:30 pmRNSDirector's Other Directorship
30th Dec 20156:00 pmRNSNet Asset Value(s)
23rd Dec 20155:00 pmRNSNet Asset Value(s)
22nd Dec 201512:00 pmRNSNet Asset Value(s)
17th Dec 20157:00 amRNSFACTSHEET - NOVEMBER 2015
16th Dec 20153:30 pmRNSNet Asset Value(s)
10th Dec 20157:00 amRNSNet Asset Value(s)
9th Dec 20155:30 pmRNSUpdate on Proposed Return of Capital
8th Dec 20156:30 pmRNSHolding(s) in Company
3rd Dec 20156:20 pmRNSNet Asset Value(s)
3rd Dec 20155:30 pmRNSHolding(s) in Company
3rd Dec 20155:30 pmRNSHolding(s) in Company
3rd Dec 20154:00 pmRNSConversion between share classes
2nd Dec 20154:05 pmRNSUpdate on Proposed Return of Capital
1st Dec 20151:20 pmRNSReturn of Capital
1st Dec 201512:15 pmRNSTotal Voting Rights
30th Nov 20155:40 pmRNSTransaction in Own Shares
27th Nov 20156:20 pmRNSTransaction in Own Shares
26th Nov 20155:30 pmRNSTransaction in Own Shares
25th Nov 20155:40 pmRNSTransaction in Own Shares
25th Nov 20151:45 pmRNSNet Asset Value(s)
24th Nov 20155:45 pmRNSTransaction in Own Shares
23rd Nov 20155:45 pmRNSTransaction in Own Shares
20th Nov 20155:30 pmRNSTransaction in Own Shares
20th Nov 20153:15 pmRNSNet Asset Value(s)
20th Nov 20157:00 amRNSStatement re Continuation Vote
19th Nov 20156:00 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.